Article
Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.
Journal of molecular neuroscience : MN - 1 Jan 2004
Refolo Lorenzo M, Fillit Howard M
Abstract excerpt
The identification of factors that influence the onset or progression of the sporadic form of Alzheimer's disease (AD) is a key step toward understanding its mechanism(s) and developing successful rational therapies. The apoE genotype has been identified as a powerful risk factor for AD that may account for as much as 50% of the sporadic form of the disease. As the major risk factor for late-onset AD,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
